Industry Pipeline - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Pipeline
Pre-Interphex 2010 Product Releases.

Pharmaceutical Technology
Volume 34, Issue 3, pp. 83-87

PACKAGING EQUIPMENT & SUPPLIES



Brand-protection technology
NanoEncryption technology is on-dose brand-protection technology that enables manufacturers to trace and authenticate every dose from plant to patient. The technology possesses security features at the overt, covert, and forensic levels and can be applied directly to tablets, capsules, and vial caps. NanoGuardian, Skokie, IL http://www.nanoink.net/ tel. 847.679.6266



Packaging solution
The NextBottle package from Catalent and One World Design and Manufacturing Group is designed to improve patient compliance. The product's dial mechanism dispenses one pill at a time and automatically reminds patients of the last day that a pill was taken. Catalent Pharma Solutions, Somerset, NJ http://www.catalent.com/ tel. 866.720.3148



Integrated blister line
The Giant1 integrated blister line fully responds to sophisticated production requirements worldwide. The line is an alternative for the timely production of small and medium-sized batches. The unit produces as many as 350 blisters/min and 175 cartons/min. The machine provides flexible operation and changeover and easy cleaning. IMA Group, Bristol, PA http://www.ima.it/ tel. 215.826.8500


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here